An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Research Triangle Park, North Carolina, United States, 27709
- Glaxo Wellcome Inc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients must have HIV reactivity.
- Patients must belong to one of the following three groups according to the CDC classification:
- IIB - including only those patients with autoimmune thrombocytopenia (platelet count = or < 100000 platelets/mm3).
- OR Lymphopenia (lymphocyte count = or < 1000 cells/mm3).
- OR Helper cell lymphopenia (helper cells < the mean of normals).
- OR CDC classification III or IV-C2.
- Patients with = or < involuntary 10 percent weight loss in the last 6 months.
- ECOG performance status 0 or 1.
- Weigh 70 kg + or - 15 kg in order to standardize the g/kg dosing.
- Positive antibody for HIV by an ELISA test kit. If the ELISA is negative, then eligibility will be confirmed by second confirmatory test, i.e., immunoblot.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- AIDS or the CDC classification stage IV except stage IV-C2.
- HIV antibody negative by immunoblot.
- Persistent fevers of > 38.5 degrees C.
- Persistent diarrhea undiagnosed > 1 month.
- Involuntary weight loss of > 10 percent in the 6 months prior to study entry.
- ECOG performance status of 2, 3, or 4.
- Class IV-C2 with prior history of:
- Multidermal herpes zoster.
- Oral candidiasis on more than one occasion.
- Tuberculosis.
Concurrent Medication:
Excluded:
- Other antiretroviral agents.
- Active immunomodulating agents.
- Any other experimental therapy.
- Drugs which cause anemia or neutropenia.
- Drugs which are glucuronidated and may interfere with the metabolism of AZT, i.e., acetaminophen > 5 days.
- Acyclovir systemically administered > 5 days.
- Any other experimental agents.
Patients with the following are excluded:
- AIDS or the CDC classification stage IV except stage IV-C2.
- HIV antibody negative by immunoblot.
- Persistent fevers of > 38.5 degrees C.
- Persistent diarrhea undiagnosed > 1 month.
- Involuntary weight loss of > 10 percent in the 6 months prior to study entry.
- ECOG performance status of 2, 3, or 4.
- Class IV-C2 with prior history of:
- Multidermal herpes zoster.
- Oral candidiasis on more than one occasion.
- Tuberculosis.
Prior Medication:
Excluded within 3 months of study entry:
- Other antiretroviral agents. Active immunomodulating agents.
- Excluded within 2 weeks of study entry:
- Drugs which cause anemia or neutropenia.
- Drugs which are glucuronidated and may interfere with the metabolism of zidovudine (AZT), i.e., acetaminophen > 5 days.
- Acyclovir systemically administered > 5 days.
- Any other experimental agents.
Known active drug abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Zidovudine
Other Study ID Numbers
Other Study ID Numbers
- 014C
- 013 (Nahrain Medical Research Collective (NMRC))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.